FDA Approves Regeneron’s Libtayo for High-Risk Skin Cancer as Adjuvant Therapy

October 13, 2025

Breakthrough Antibiotic Shows Promise Against Resistant Gonorrhea

February 27, 2024

Novartis Lets Go of Phase 2 Radioligand Therapy Following Clinic Disappointment

July 23, 2026

Must Read

Why Data Is Becoming Pharma’s Most Valuable Asset

August 17, 2026

PTC Therapeutics Acquires ST-920 Fabry Disease Gene Therapy Program From Sangamo

August 17, 2026

Zealand Bags Huge Money By Selling Rights to Takeda’s Blood Cancer Drug

August 17, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Biogen’s Phase 2 Diranersen Data Shows Reduced Cognitive Decline in Alzheimer’s Disease

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Taiho and Cullinan Report Phase 3 Progression-Free Survival Win for Zipalertinib

MoonLake Reports Positive Phase 3 Results for Sonelokimab in Psoriatic Arthritis

Merck’s Tulisokibart Misses Phase 2 Endpoint in SSc-ILD but Meets Goals in HS Trial

After phase 3 data ended blockbuster hopes, GSK eliminated a major cough medication candidate

PTC Therapeutics Acquires ST-920 Fabry Disease Gene Therapy Program From Sangamo

Zealand Bags Huge Money By Selling Rights to Takeda’s Blood Cancer Drug

Eli Lilly Files Six Lawsuits Over Sales of Unapproved Retatrutide

Claryx Appears From Stealth to Deal with the $45B Hospital-Acquired Infections Issue

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

Why Data Is Becoming Pharma’s Most Valuable Asset

Reinventing the Pharmaceutical Commercial Model

Top 10 Strategic Priorities for Pharma CEOs in 2027

Top 10 Trends Reshaping Pharmaceutical Sales

Tag: IDEAYA

IDEAYA and Servier Report Phase 2/3 Trial Success for Darovasertib Combination in Uveal Melanoma

Editor Picks

FDA Approves Regeneron’s Libtayo for High-Risk Skin Cancer as Adjuvant Therapy

Breakthrough Antibiotic Shows Promise Against Resistant Gonorrhea

Novartis Lets Go of Phase 2 Radioligand Therapy Following Clinic Disappointment

Must Read

Why Data Is Becoming Pharma’s Most Valuable Asset

PTC Therapeutics Acquires ST-920 Fabry Disease Gene Therapy Program From Sangamo

Zealand Bags Huge Money By Selling Rights to Takeda’s Blood Cancer Drug

Hot Topics

About Us

Follow Us